Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neuroradiology
Published in: Neuroradiology 8/2004

01-08-2004 | Diagnostic Neuroradiology

A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours

Authors: C. Colosimo, M. V. Knopp, X. Barreau, E. Gérardin, M. A. Kirchin, F. Guézénoc, K. P. Lodemann

Published in: Neuroradiology | Issue 8/2004

Login to get access

Abstract

A two-centre intra-individual crossover study was performed in 23 patients with suspected high-grade glioma or metastases to assess and compare the safety and enhancement characteristics of two different MRI contrast media (gadobenate dimeglumine, Gd-BOPTA and gadoterate meglumine, Gd-DOTA) at equivalent doses of 0.1 mmol/kg body weight. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and T1-weighted images 0, 2, 4, 6, 8 and 15 min after injection. T1-weighted images with magnetisation transfer contrast were acquired 12 min after injection. Qualitative assessment by blinded, off-site readers (reader 1: 19 patients; reader 2: 21) and on-site investigators (23) revealed significant (P ≤0.005) overall preference for Gd-BOPTA over Gd-DOTA for contrast enhancement (Gd-BOPTA preferred in 18, 15 and 18 cases; Gd-DOTA in 0, 1 and 1 and no preference in 1, 5 and 4; off-site readers 1 and 2, and on-site investigators, respectively). A similar significant preference for Gd-BOPTA was expressed by off-site readers and on-site investigators for lesion-to-brain contrast, lesion delineation, internal lesion structure, and overall image preference. Quantitative assessment by off-site readers revealed significantly (p<0.05) greater lesion enhancement with Gd-BOPTA than with Gd-DOTA at all times from 2 min after injection.
Literature
1.
Healy ME, Hesselink JR, Press GA, Middleton MS (1987) Increased detection of intracranial metastases with intravenous Gd-DTPA. Radiology 165: 619–624PubMed
2.
3.
Runge VM, Muroff LR, Wells JW (1997) Principles of contrast enhancement in the evaluation of brain diseases: an overview. J Magn Reson Imaging 7: 5–13PubMed
4.
de Haën C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl. 1]: S161–S168
5.
Yuh WTC, Fisher DJ, Engelken JD, et al (1991) MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180: 485–491PubMed
6.
Myhr G, Rinck PA, Børseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33: 405–409PubMed
7.
Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35: 490–494PubMed
8.
Valk J, Algra PR, Hazenberg CJ, Slooff WBM, Slavand MG (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35: 173–177PubMed
9.
Brugières P, Gaston A, Degryse HR, et al (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36: 27–30PubMed
10.
Åkeson P, Jonsson E, Haugen I, Holtas S (1995) Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 37: 229–233CrossRefPubMed
11.
Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30: 75–78PubMed
12.
Grossman RI, Rubin DI, Hunter G, et al (2000) Magnetic resonance imaging in patients with central nervous system pathology. A comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35: 412–419CrossRefPubMed
13.
Greco A, Parker JR, Ratcliffe CG, Kirchin MA, McNamara MT (2001) Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45: 457–463CrossRefPubMed
14.
Runge VM, Kirsch JE, Burke VJ, et al (1992) High dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2: 9–18PubMed
15.
Yuh WTC, Engelken JD, Muhonen MG, Fisher DJ, Erhardt JC (1992) Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. AJNR 13: 335–345PubMed
16.
Haustein J, Laniado M, Niendorf H-P, et al (1993) Triple dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186: 855–860PubMed
17.
Yuh WTC, Halloran JI, Mayr NA, Fisher DJ, Nguyen HD, Simonson TM (1994) Dose of contrast material in the MR imaging evaluation of central nervous system tumors. J Magn Reson Imaging 4: 242–249
18.
Yuh WTC, Fisher DJ, Runge VM, et al (1994) Phase III multicenter trial of high dose gadoteridol in MR evaluation of brain metastases. AJNR 15: 1037–1051PubMed
19.
Yuh WTC, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ (1995) The effect of contrast dose, imaging time and lesion size in the MR detection of intracerebral metastasis. AJNR 16: 373–380PubMed
20.
Van Dijk P, Sijens PE, Schmitz PI, Oudkerk M (1997) Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 15: 535–541PubMed
21.
Sze G, Johnson C, Kawamura Y, et al (1998) Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR 19: 821–828PubMed
22.
Yuh WTC, Maley JE (1998) Contrast dosage in the neuroimaging of brain tumors. Magn Reson Imaging Clin North Am 6: 113–124
23.
Anon. ProHance® (gadoteridol injection) package insert. Bracco Diagnostics, Princeton
24.
Anon. Omniscan® (gadodiamide injection) package insert. Nycomed-Amersham, Princeton
25.
Cavagna FM, Maggioni F, Castelli PM, et al (1997) Gadolinium chelates with weak binding to serum proteins. Invest Radiol 32: 780–796PubMed
26.
Colosimo C, Ruscalleda J, Korves M, et al (2001) Detection of intracranial metastases: a multi-center, intra-patient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dose. Invest Radiol 36: 72–81PubMed
27.
Runge VM, Armstrong MR, Barr RG, et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36: 65–71PubMed
28.
Runge VM, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37: 269–280CrossRefPubMed
29.
Schneider G, Kirchin MA, Pirovano G, et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 14: 525–539CrossRefPubMed
30.
Balériaux D, Colosimo C, Ruscalleda J, et al (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44: 191–203CrossRefPubMed
31.
Cohen J (1960) A coefficient of agreement for nominal scales. Educ Psychol Measurement 20: 37–46
32.
Koch GG (1972) The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 28: 577–584PubMed
33.
Parizel PM, Degryse HR, Gheuens J, et al (1989) Gadolinium-DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13: 378–385
34.
Knopp MV, Runge VM, Essig M, et al (2004) Primary and secondary brain tumors: a bicentric intra-individual crossover comparison of gadobenate dimeglumine with gadopentetate dimeglumine for lesion enhancement. Radiology 230: 55–64PubMed
35.
Knopp MV, Schoenberg SO, Rehm C, et al (2002) Assessment of gadobenate dimeglumine (Gd-BOPTA) for MR angiography: phase I studies. Invest Radiol 37: 706–715CrossRefPubMed
36.
Völk M, Strotzer M, Lenhart M, et al (2001) Renal time-resolved MR angiography: quantitative comparison of gadobenate dimeglumine and gadopentetate dimeglumine with different doses. Radiology 220: 484–488PubMed
37.
Schneider G, Maas R, Schultze Kool L, et al (2003) Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 38: 85–94CrossRefPubMed
38.
Seitz RJ, Wechsler W (1987) Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol (Berl) 73: 145–152
39.
Finelli DA, Hurst GC, Gullapali RP, Bellon EM (1994) Improved contrast of enhancing brain lesions on post-gadolinium, T1-weighted spin-echo images with use of magnetization transfer. Radiology 190: 553–559PubMed
Metadata
Title
A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours
Authors
C. Colosimo
M. V. Knopp
X. Barreau
E. Gérardin
M. A. Kirchin
F. Guézénoc
K. P. Lodemann
Publication date
01-08-2004
Publisher
Springer-Verlag
Published in
Neuroradiology / Issue 8/2004
Print ISSN: 0028-3940
Electronic ISSN: 1432-1920
DOI
https://doi.org/10.1007/s00234-003-1128-4

Other articles of this Issue 8/2004

Neuroradiology 8/2004 Go to the issue

Book Review

T. Juroiwa, A. Baethmann, Z. Czernicki Z et al. (eds): Brain Oedema XII: Proceedings of the 12th International Symposium

Paediatric Neuroradiology

Posterior pericallosal lipoma extending through the interhemispheric fissure into the scalp via the anterior fontanelle

Diagnostic Neuroradiology

Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma

Diagnostic Neuroradiology

Transluminal color-coded three-dimensional magnetic resonance angiography for visualization of signal Intensity distribution pattern within an unruptured cerebral aneurysm: preliminarily assessment with anterior communicating artery aneurysms

Interventional Neuroradiology

Acute stenting and thromboaspiration in basilar artery occlusions due to embolism from the dominating vertebral artery

Book Review

T. Moritani, S. Ekholm, P.-L. Westesson: Diffusion-Weighted MR Imaging of the Brain